The existence of several TNF inhibitors (e.g., infliximab, adalimumab, etc.)in the market and the current ongoing clinical trials highlight the clinical importance of this molecule in the treatment of diseases such as systemic rheumatic disease and inflammatory bowel disease [48]. Here, TNF is linked to inflammatory bowel disease.